ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2649

Defining Clinical Subgroups of Patients with Relapsing Polychondritis: A Latent Class and Decision Tree Analysis in Two Independent Prospective Cohorts

Shubhasree Banerjee1, Carol McAlear2, Peter Merkel3, Peter Grayson4 and Marcela Ferrada5, 1University of Pennsylvania, Philadelphia, 2University of Pennsylvania, Philadelphia, PA, 3Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, 5University of Maryland, Baltimore, MD

Meeting: ACR Convergence 2024

Keywords: cartilage, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Lack of awareness and disease heterogeneity are common factors associated with diagnosis delay in patients with Relapsing polychondriytis (RP). Using latent class analysis (LCA), phenotypic subgroups have been identified in a prospective cohort of patients with RP.  Identifying these subgroups can help clinicians to recognize patterns of organ involvement, facilitating prompt diagnosis.This study aimed to validate previously identified clinical subgroups using LCA and develop a decision tree algorithm to accurately predict assignment of individual patients to these subgroups.

 

Methods: Patients ≥ 18 years old who met diagnostic criteria for RP were included. All patients had a dynamic chest computerized tomography (CT) and audiometry. LCA was conducted in two independent prospective cohorts of patients with RP using the following variables: arthritis, tracheomalacia, bronchomalacia, subglottic stenosis, ear damage, nose damage, eye inflammation, and sensorineural hearing loss. Ear damage was defined by thickening of the cartilage or cauliflower ear. Nose damage was defined by saddle nose deformity or nasal septal perforation. Tracheomalacia and bronchomalacia were defined as ≥ 50% airway collapse on dynamic chest CT. Optimization of latent class models was performed using Bayesian information criterion (BIC) and Akaike information criterion (AIC). Decision tree analysis was performed to predict latent class group status.

Results: 162 patients with RP were included in this study. Cohort #1 included 102 patients: 92 (90%) females; 93 (91%) Caucasians; median age 48 years (IQR= 38-59).  Cohort #2 included 60 patients: 52 (86%) females; 52 (86 %) Caucasians; median age 44 years (IQR=38-52).

Three clinical subgroups were identified by LCA in each cohort: Type 1 was characterized by ear damage, nose damage and subglottic stenosis, Type 2 was characterized by tracheomalacia and bronchomalacia, and Type 3 was characterized by absence of tracheomalacia.

Tracheomalacia and ear damage were the two critical variables found on the decision tree that predicted latent class assignment in both cohorts. In cohort #1, the accuracy was 98% (R-square = 0.91) and in cohort #2 the accuracy was 100% (R-square=0.95) (Figure 1).

Figure 1 

Figure 1. Decision tree analysis to classify patients with relapsing polychondritis into three subgroups defined by latent class analysis.

Conclusion: This study corroborates the existence of previously identified clinical subtypes of RP. Tracheomalacia and ear damage effectively categorize patients into these subgroups. These findings support the potential use of this subgrouping in clinical practice and clinical research design.

Supporting image 1


Disclosures: S. Banerjee: None; C. McAlear: None; P. Merkel: AbbVie/Abbot, 2, AstraZeneca, 2, Boehringer Ingelheim, 2, GlaxoSmithKlein(GSK), 2, Roche, 5; P. Grayson: None; M. Ferrada: None.

To cite this abstract in AMA style:

Banerjee S, McAlear C, Merkel P, Grayson P, Ferrada M. Defining Clinical Subgroups of Patients with Relapsing Polychondritis: A Latent Class and Decision Tree Analysis in Two Independent Prospective Cohorts [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/defining-clinical-subgroups-of-patients-with-relapsing-polychondritis-a-latent-class-and-decision-tree-analysis-in-two-independent-prospective-cohorts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/defining-clinical-subgroups-of-patients-with-relapsing-polychondritis-a-latent-class-and-decision-tree-analysis-in-two-independent-prospective-cohorts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology